ArticlemBio2022
Accessory Genomes Drive Independent Spread of Carbapenem-Resistant Klebsiella pneumoniae Clonal Groups 258 and 307 in Houston, TX.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Advances in CRISPR-Cas for Diagnosis and Treatment ofPathogens (Basel, Switzerland) · 2026Review
- Carbapenem-resistantbioRxiv : the preprint server for biology · 2026Article
- Regional surveillance of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Plasmid diversity in Klebsiella pneumoniae ST307 co-producing KPC plus NDM recovered during the COVID-19 pandemic.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2025Article
- Evaluation of capsule polysaccharide (CPS)-specific antibodies for broad recognition of prominent multidrug-resistantMicrobiology spectrum · 2025Article
- Integration sites ofFrontiers in microbiology · 2025Article
- Epidemiology, antimicrobial resistance profile, associated risk factors and management of carbapenem resistant Klebsiella pneumoniae in children under 5 with suspected sepsis in Ethiopia.BMC infectious diseases · 2024Article
- Article
- ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics.Nature reviews. Microbiology · 2024Review
- Clonal background and routes of plasmid transmission underlie antimicrobial resistance features of bloodstream Klebsiella pneumoniae.Nature communications · 2024Article
- In-depth characterization of multidrug-resistant NDM-1 and KPC-3 co-producingMicrobiology spectrum · 2024Article
- Diverse Role ofAntibiotics (Basel, Switzerland) · 2024Article
- Identification of a novel CG307 sub-clade in third-generation-cephalosporin-resistantMicrobial genomics · 2024Article
- Plasmid genomic epidemiology ofAntimicrobial agents and chemotherapy · 2023Article
- Genomics and Antimicrobial Susceptibility of ClinicalPathogens (Basel, Switzerland) · 2023Article
- A panel of diverseMicrobial genomics · 2023Article
- Staphylococcus aureus Breast Implant Infection Isolates Display Recalcitrance To Antibiotic Pocket Irrigants.Microbiology spectrum · 2023Article
- Ceftazidime-avibactam resistance inMicrobial genomics · 2023Article
- A Comprehensive Genomic Analysis of the EmergentPathogens (Basel, Switzerland) · 2022Article
- The Genetic Characteristics and Carbapenem Resistance Mechanism of ST307Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 15 institutions in 1 country.
William C ShropshireCenter for Infectious Diseases, School of Public Health, University of Texas Health Science Center, Houston, Texas, USA.
An Q DinhDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Michelle EarleyThe Biostatistics Center, The George Washington Universitygrid.253615.6, Rockville, Maryland, USA.
Lauren KomarowThe Biostatistics Center, The George Washington Universitygrid.253615.6, Rockville, Maryland, USA.
Diana PanessoDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Kirsten RydellDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Sara I Gómez-VillegasDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Hongyu MiaoDepartment of Biostatistics and Data Science, School of Public Health, University of Texas Health Science Center, Houston, Texas, USA.
Carol HillDuke Clinical Research Institute, Duke Universitygrid.26009.3d Medical Center, Durham, North Carolina, USA.
Liang ChenCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0001-5845-2235
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA.ORCID 0000-0001-6344-4141
Bettina C FriesDepartment of Medicine, Infectious Disease Division, Stony Brook Universitygrid.36425.36, Stony Brook, New York, USA.
Lilian AbboDivision of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine and Jackson Health System, Miami, Florida, USA.
Eric CoberDepartment of Infectious Diseases, Cleveland Clinicgrid.239578.2, Cleveland, Ohio, USA.
Sara RevolinskiSchool of Pharmacy, Medical College of Wisconsingrid.30760.32, Milwaukee, Wisconsin, USA.ORCID 0000-0001-8810-2359
Courtney L LuterbachDivision of Infectious Diseases, University of North Carolina at Chapel Hillgrid.10698.36, Raleigh, North Carolina, USA.
Henry ChambersDepartment of Medicine, University of California San Francisco, San Francisco, USA.
Vance G FowlerDivision of Infectious Diseases, Duke Universitygrid.26009.3d, Durham, North Carolina, USA.
Robert A BonomoCenter for Antimicrobial Resistance and Microbial Genomics, Division of Infectious Diseases, University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA.ORCID 0000-0002-3299-894X
Samuel A ShelburneCenter for Antimicrobial Resistance and Microbial Genomics, Division of Infectious Diseases, University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA.ORCID 0000-0001-9721-263X
Barry N KreiswirthCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-0243-131X
David van DuinDivision of Infectious Diseases, University of North Carolina at Chapel Hillgrid.10698.36, Raleigh, North Carolina, USA.ORCID 0000-0003-4784-3227
Blake M HansonCenter for Infectious Diseases, School of Public Health, University of Texas Health Science Center, Houston, Texas, USA.ORCID 0000-0003-2949-7818
Cesar A AriasDivision of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
Houston Methodist · USThe University of Texas Health Science Center at Houston · USGeorge Washington University · USHackensack Meridian Health · USUniversity of North Carolina at Chapel Hill · USCleveland Clinic · USClinical Research Institute · USDuke University · USLouis Stokes Cleveland VA Medical Center · USMayo Clinic · USMedical College of Wisconsin · USNorthport VA Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Miami · US
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8MProject 3: Functional Microbiome and Host Signatures in Transition from Commensal to pathogenP01AI152999 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HAAG, ANTHONY · 2020 to 2025
$12.0MVENOUS: A translational study of enterococcal bacteremiaR01AI148342 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2020 to 2024
$3.9MThe LiaFSR system and antimicrobial peptide resistance in enterococciR01AI134637 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Cesar Augusto Arias · 2018 to 2026
$3.7MBacterial Characteristics of Community-associated Carbapenem-Resistant EnterobacteriaceaeR01AI143910 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAN DUIN, DAVID · 2019 to 2023
$1.9MPOR Program on Genomic Prediction of Antimicrobial Resistance in VREK24AI121296 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2016 to 2025
$1.5MMobile Genetic Elements and Clinical Outcomes in Staphylococcus aureus BacteremiaK01AI148593 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI HANSON, BLAKE M · 2020 to 2023
$519kMolecular basis of the cefazolin inoculum effectR21AI143229 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARIAS, CESAR AUGUSTO · 2019 to 2020
$442kBLRD VA I01 BX003741NIAID NIH HHS K01 AI148593NIAID NIH HHS K24 AI121296NIAID NIH HHS P01 AI152999NIAID NIH HHS R01 AI134637NIAID NIH HHS R01 AI143910NIAID NIH HHS R01 AI148342NIAID NIH HHS R21 AI143229NIAID NIH HHS UM1 AI104681
Abstract
Carbapenem-resistant Klebsiella pneumoniae (CR
Indexed as
Carbapenem-Resistant EnterobacteriaceaeKlebsiella InfectionsCarbapenemsHumansKlebsiella pneumoniaeProspective StudiesCarbapenemscarbapenem-resistant Klebsiella pneumoniaeCG258CG307divergent evolutiongenomic surveillancemobile genetic elements
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.